About Plus Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: http://www.plustherapeutics.com/
Frequently Asked Questions
What is the 52-week range for CNSY?
The 52-week high is $4.1599 and the 52-week low is $1.54.
What is the P/E ratio for CNSY?
The P/E ratio data is currently unavailable.
What is the dividend yield for CNSY?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -394.17%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -620.70%.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for CNSY over the last few months:
Latest CNSY News
Lake Street Maintains Buy on Cerenome, Lowers Price Target to $31
Lake Street analyst Chad Messer maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $50 to $31.
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform September 30, 2026 8:30 AM EDTCompany ParticipantsMarc Hedrick...
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer billings, progress on Medicare coverage of its Tumor Cell Enumeration Test (TCE Tes
Cerenome Anticipates $1.55M In Payer Billings In Q3
Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company") today provided a third quarter 2026 business update for its wholly owned subsidiary, CNSide Diagnostics, LLC, highlighting gross payer
Cerenome to Hold CNSide® Business Update Call on September 30, 2026
Management to provide updates on recent developments including diagnostic billing, market access & growth plansHOUSTON, Sept. 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announced that management will host a conference call and webcast on Wednesday, September 30, 2026, at 8:30 a.m. Eastern Time to provide a business update on CNSide®, the Company's cerebrospinal fluid (CSF) diagnostic platfo
Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (“BCBSM”), effective September 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. BCBSM serves approximately 5 million commercial and Medicare Advantage members through Blue Cross Blue Shiel
Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division
HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), today announces the appointment of Samantha Fowlkes as Vice President Head of Commercial Sales. Samantha will lead the commercial expansion of CNSide®, strengthening relationships across the oncology and pathology communities, and accelerate adoption of the CNSide platform by physicians and health systems. “Samantha brings more than two de
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday
Analysts raised targets for Darden, ServiceNow, Robinhood, Ibex and Workiva, while cutting targets for McDonald’s, Cerenome and Wingstop.
Ascendiant Capital Maintains Buy on Cerenome, Lowers Price Target to $43
Ascendiant Capital analyst Edward Woo maintains Cerenome (NASDAQ:CNSY) with a Buy and lowers the price target from $57 to $43.
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Capital will support continued CNSide® commercial scale-up and development Initial tranche of funding provided at closing with future tranches linked to milestones Forecasted cash runway now into 2028 HOUSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform of precision diagnostics, targeted therapeutics, and artificial intelligence, today announced that it has entered into a financing agreeme
Cerenome Enters Financing Agreement With 3i Fund For Senior Secured Facility Of Up To $20M With Royalty-Based Repayments
Under the agreement, the Company received initial funding at closing, with future tranches available upon achieving certain milestones. The financing is intended to support the scale-up of the Company’s proprietary
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-10-01 | ANDREWS RONALD ASBURY | -921 | - | - |
| 2026-10-01 | ANDREWS RONALD ASBURY | +921 | - | - |
| 2026-10-01 | Clowes Howard | -921 | - | - |
| 2026-10-01 | Clowes Howard | +921 | - | - |
| 2026-10-01 | van Es-Johansson An | -921 | - | - |
| 2026-10-01 | van Es-Johansson An | +921 | - | - |
| 2026-10-01 | Hawkins Richard J | -921 | - | - |
| 2026-10-01 | Hawkins Richard J | +921 | - | - |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | -287 | - | - |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | -1,165 | - | - |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | -1,533 | - | - |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | +287 | - | - |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | +1,165 | - | - |
| 2026-10-01 | Sims Andrew John Hugh MacIntyre | +1,533 | - | - |
| 2026-10-01 | HEDRICK MARC H | -1,986 | - | - |
| 2026-10-01 | HEDRICK MARC H | -8,066 | - | - |
| 2026-10-01 | HEDRICK MARC H | -6,387 | - | - |
| 2026-10-01 | HEDRICK MARC H | +1,986 | - | - |
| 2026-10-01 | HEDRICK MARC H | +8,066 | - | - |
| 2026-10-01 | HEDRICK MARC H | +6,387 | - | - |
| 2026-10-01 | Guse Kyle | -921 | - | - |
| 2026-10-01 | Guse Kyle | +921 | - | - |